Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000908834-25-000061
Filing Date
2025-02-11
Accepted
2025-02-11 12:11:10
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 40479
2 JOINT ACQUISITION STATEMENT jas.htm EX-1 10608
  Complete submission text file 0000908834-25-000061.txt   52928
Mailing Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111
Business Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111 (415) 421-2132
Farallon Capital Partners, L.P. (Filed by) CIK: 0001175707 (see all company filings)

EIN.: 943106322 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 4 KINGSBURY AVENUE WATERTOWN MA 02472
Business Address 4 KINGSBURY AVENUE WATERTOWN MA 02472 617 607 0800
ENANTA PHARMACEUTICALS INC (Subject) CIK: 0001177648 (see all company filings)

EIN.: 043205099 | Fiscal Year End: 0930
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87373 | Film No.: 25608518
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)